BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  CinCor Reports First Quarter 2022 Financial Results and Provides Corporate Update

  CinCor Pharma, Inc. announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.

  May 10, 2022

   · 

  9 min read
• Business

  Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

  Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the quarter ended March 31, 2022 and clinical development updates.

  May 10, 2022

   · 

  14 min read
• Business

  Freeline Reports First Quarter 2022 Financial Results and Business Highlights

  Freeline Therapeutics Holdings plc reported financial results for the first quarter of 2022 and provided a business update.

  May 10, 2022

   · 

  12 min read
• Business

  Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the first quarter ended March 31, 2022.

  May 10, 2022

   · 

  8 min read
• Business

  TELA Bio Reports First Quarter 2022 Financial Results

  TELA Bio, Inc. reported financial results for the first quarter ended March 31, 2022.

  May 10, 2022

   · 

  7 min read
• Business

  Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates

  Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today reported financial results for the quarter ended March 31, 2022 and provided operational updates.

  May 10, 2022

   · 

  12 min read
• Pharm Country

  Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA

  Amicus Therapeutics announced that the U.S. Food and Drug Administration has extended the review period by 90 days for the Biologics License Application for cipaglucosidase alfa and the New Drug Application for miglustat, the two components of AT-GAA.

  May 10, 2022

   · 

  5 min read
• Drug Development

  Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Arcellx, Inc. announced that the first patient has been dosed in its open-label, multicenter ACLX-001 Phase 1 clinical trial to evaluate the company’s novel ARC-SparX program in patients with relapsed or refractory multiple myeloma.

  May 10, 2022

   · 

  6 min read
• Business

  Halozyme Reports First Quarter 2022 Results

  Halozyme Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided an update on its recent corporate activities and outlook.

  May 10, 2022

   · 

  17 min read
• Business

  Sera Prognostics Reports First Quarter 2022 Financial Results

  Sera Prognostics Inc., The Pregnancy Company®, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced financial results for the first quarter ended March 31, 2022.

  May 10, 2022

   · 

  9 min read